| Agent |
PFS |
OS |
QOL |
ORR |
| 1.Angiogenesis inhibitors
1a.Antibodies, peptides
Bevacizumab
Adjuvant setting
Burger [12]
|
14.1 vs 11.2 vs 10.3 mos,
HR 0.717, p<0.0001 |
No difference |
Lower in bev arm during chemo |
|
| Oza[13] |
20.3 vs 21.8 mos
HR 0.81 95%CI 0.70-0.94, p=0.0041 |
No difference |
|
|
| Recurrent – Platinum sensitive
Aghajanian[15] |
12.4 vs 8.4 mos,
HR 0.484 95%CI 0.388-0.605, P<0.0001 |
No difference |
|
78.5% vs 57.4% p<0.0001 |
| Recurrent – Platinum resistant
Pujade-Lauraine[16] |
6.7 vs 3.4 mos
HR 0.48 95%CI 0,38-0.60, p<0.001 |
No difference |
|
|
| Trebananib
Monk [28] |
7.2 vs 5.4 mos
HR 0.66 95%CI 0.57-0.77, p<0.001 |
No difference |
|
|
| 1b.Small Molecule inhibitors
Targeting VEGFR and c-kit
Cediranib
Recurrent -Platinum sensitive
Ledermann[35] |
12.6 vs 9.4 mos,
HR 0.57 95%CI 0.45-0.74, p=0.00001 |
20.6 vs 17.6 mos HR 0.70p=0.419 |
|
|
| Nintedanib
Baumann [37] |
17.3 vs 16.6 mos,
HR 0.84, 95% CI 0.72-0.98, p=0.0239 |
No difference |
|
|
| Targeting VEGFR, PDGFR, c-kit
Pazopanib
Adjuvant
Du Bois [43] |
17.9 vs 12.3 mos,
HR 0.766, 95%CI 0.64-0.91, p=0.0021 |
|
|
|
| 2. EGF Inhibitors
2a. Antibodies
Pertuzumab |
|
|
|
14% vs 5% |
| 3. Targeting folate receptor alpha
Farletuzumab
Recurrent – Platinum resistant
Walters [54]
Recurrent – Platinum sensitive
Vergote[55] |
No benefit
No benefit |
|
|
|
| EC145
Recurrent – Platinum resistant
Naumann[57] |
Pending |
|
|
|
| 8. Inhibition of DNA repair
Olaparib
Adjuvant-maintenance
Lheueux[76]
Recurrent -Platinum sensitive
(NCT01874353) |
Pending
Pending |
|
|
|
| Niraparib
Recurrent – Platinum sensitive
(NCT01847274) |
Pending |
|
|
|
| Rucaparib
Recurrent – Platinum sensitive
(NCT01968213) |
Pending |
|
|
|
